Spruce Street Capital LP
CIK 2050194 · 在 SEC EDGAR 上查看 ↗
- 投资组合价值
- $509.7M
- 持仓
- 30
- 截至
- 2026年6月30日
按 13F 价值排名第 3726（共 9443） · 前 39.5%
投资组合价值同比（季度）：+22.5% 13F不披露现金
- 前十大持仓权重
- 70.24%
- 前二十五大持仓权重
- 96.58%
- 持仓高于 1%
- 24
- 有效持仓数量
- 16.0
仅基于13F多头股票持仓（现金、债券、空头未披露）
周转率 Q2 2026: 9.79% 估计买入 $62623670 · 卖出 $45296407
- 新仓位
- 5
- 增加
- 8
- 减少
- 1
- 已结清
- 3
本页内容
行业细分
Healthcare
94.4%
其他/未映射
5.6%
完整投资组合 30 持仓
| 类型 | 连胜 | 8个季度趋势 | |||||
|---|---|---|---|---|---|---|---|
| KNSA Kiniksa Pharmaceuticals International, plc - Class A Ordinary Shares | $58710577 | 11.52% | 918070 | $22065394 | 上涨 ×2 | ||
| RLAY Relay Therapeutics, Inc. - Common Stock | $55832979 | 10.95% | 2984125 | $26140935 | |||
| LBRX LB Pharmaceuticals Inc - Common Stock | $44663240 | 8.76% | 1376159 | $11018374 | |||
| RLMD Relmada Therapeutics, Inc. - Common Stock | $44227990 | 8.68% | 6391328 | $1229782 | 上涨 ×2 | ||
| ANRO Alto Neuroscience, Inc. Common Stock | $35706910 | 7.01% | 1353047 | $6590589 | 上涨 ×2 | ||
| DNTH Dianthus Therapeutics, Inc. - Common Stock | $34587464 | 6.79% | 354816 | $3262310 | 下跌 ×1 | ||
| ALKS Alkermes plc - Ordinary Shares | $28496383 | 5.59% | 543876 | $17252186 | 上涨 ×1 | ||
| SVRA Savara, Inc. - Common Stock | $21267868 | 4.17% | 3452576 | $2795732 | 上涨 ×2 | ||
| PCVX Vaxcyte, Inc. - Common Stock | $17790512 | 3.49% | 306047 | $3512362 | 上涨 ×1 | ||
| ELVN Enliven Therapeutics, Inc. - Common Stock | $16697055 | 3.28% | 329006 | $3800020 | |||
| ENTA Enanta Pharmaceuticals, Inc. - Common Stock | $15873698 | 3.11% | 1088731 | $4094985 | 上涨 ×2 | ||
| CATX | $12596305 | 2.47% | 3693931 | $1641269 | 上涨 ×1 | ||
| IFRX InflaRx N.V. - Common Stock | $11988924 | 2.35% | 5352198 | 上涨 ×1 | |||
| SRZN Surrozen, Inc. - Common Stock | $11211438 | 2.20% | 432040 | $-1373887 | |||
| ALMS Alumis Inc. - Common Stock | $11047032 | 2.17% | 392574 | $2398627 | |||
| IPSC Century Therapeutics, Inc. - Common Stock | $9944682 | 1.95% | 4059054 | $771220 | |||
| NERV Minerva Neurosciences, Inc - Common Stock | $9188025 | 1.80% | 1655500 | $-786363 | |||
| SABS SAB Biotherapeutics, Inc. - Common Stock | $8574158 | 1.68% | 2198502 | $153895 | |||
| ANTX AN2 Therapeutics, Inc. - Common Stock | $8039593 | 1.58% | 1661073 | $2463723 | |||
| ERAS Erasca, Inc. - Common Stock | $7740988 | 1.52% | 422543 | $904242 | |||
| IKT Inhibikase Therapeutics, Inc. - Common Stock | $7270654 | 1.43% | 3581603 | $1253561 | |||
| 未知发行人 (CUSIP: G75226103) | $5350000 | 1.05% | 500000 | 上涨 ×1 | |||
| HLXC Helix Acquisition Corp. III - Class A Ordinary Shares | $5320000 | 1.04% | 500000 | $240000 | |||
| ZLAB Zai Lab Limited - American Depositary Shares | $5303090 | 1.04% | 279110 | 上涨 ×1 | |||
| ACHV Achieve Life Sciences, Inc. - Common Shares | $4810240 | 0.94% | 736637 | 上涨 ×1 | |||
| LXEO Lexeo Therapeutics, Inc. - Common Stock | $4322600 | 0.85% | 928593 | $-1007524 | |||
| ALEC Alector, Inc. - Common Stock | $4223147 | 0.83% | 2101068 | $-294149 | |||
| LONA LeonaBio, Inc. - Common Stock | $3618112 | 0.71% | 393701 | $-226772 | |||
| CRVS Corvus Pharmaceuticals, Inc. - Common Stock | $3459880 | 0.68% | 231585 | $71791 | |||
| 未知发行人 (CUSIP: G50765109) | $1817600 | 0.36% | 160000 | 上涨 ×1 | |||
| 无匹配项 | |||||||
最大新仓位
本季度新开仓位，按规模从大到小排序。
季度涨幅榜
已退出持仓
包含公司事件（合并、退市）——并非所有退出都是卖出
已关闭的头寸反映了 13F 报告的变更；对于指数管理人来说，这些通常是机械性的（退市、并购、指数再平衡），而不是主动决策。
| 证券 | 季度 | 先前持股数 | 先前价值 | 退出后价格 |
|---|---|---|---|---|
| CDTX | 2026年3月31日 | 232269 | $51305899 | 不再跟踪 |
| CNTA | 2026年6月30日 | 489849 | $19456802 | 不再跟踪 |
| KALV | 2026年6月30日 | 897681 | $18070319 | 不再跟踪 |
| EYPT | 2026年3月31日 | 981543 | $17932791 | -57.8% |
| OCUL | 2026年3月31日 | 783999 | $9517748 | 33.1% |
| ABVX | 2026年3月31日 | 49119 | $6623943 | 7.3% |
| HELP | 2026年3月31日 | 770000 | $6298600 | 162.1% |
| MAZE | 2026年6月30日 | 200000 | $5970000 | -2.6% |
| STRO | 2026年3月31日 | 75594 | $874623 | -12.6% |